@article{31ea557d289147eb97bc3fc0cb2655dc,
title = "Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: A clinical perspective and emerging treatment options",
abstract = "The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to respond, respond suboptimally, or experience disease relapse after treatment with imatinib. A key factor is drug resistance. The molecular mechanisms implicated in this resistance include those that involve upregulation or mutation of BCR-ABL kinase and those that are BCR-ABL independent. The clinical consequences of these molecular mechanisms of resistance for disease pathogenesis remain open for debate. This review summarizes the molecular mechanisms and clinical consequences of TKI resistance and addresses the current and future treatment approaches for patients with TKI-resistant CML.",
keywords = "BCR-ABL mutations, Molecular mechanisms, T315I",
author = "Jabbour, {Elias J.} and Cortes, {Jorge E.} and Kantarjian, {Hagop M.}",
note = "Funding Information: Medical writing support was provided by Dr. Julia Duffey of Anthemis Consulting Ltd. , and funded by Teva Pharmaceutical Industries (Frazer, PA). Teva Pharmaceutical Industries provided a single medical accuracy review of the final draft. The authors were not compensated and retained full editorial control over the content of the article. Dr. Jabbour has received honoraria from Bristol-Myers Squibb, Novartis, Pfizer, Ariad, and Teva Pharmaceutical Industries. Dr. Cortes is a consultant for Ariad, Teva Pharmaceutical Industries, and Pfizer and has received grant support from Bristol-Myers Squibb , Novartis , Ariad , Teva Pharmaceutical Industries , and Pfizer . Dr. Kantarjian has received research grants from Novartis , Bristol-Myers Squibb , Pfizer , Ariad , and ChemGenex . ",
year = "2013",
month = oct,
doi = "10.1016/j.clml.2013.03.018",
language = "English (US)",
volume = "13",
pages = "515--529",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2650",
publisher = "Cancer Media Group",
number = "5",
}